|
Sign In to gain access to subscriptions and/or personal tools.
|
Clinical and Applied Thrombosis/Hemostasis, Vol. 12, No. 4,
465-472 (2006)
DOI: 10.1177/1076029606293433
Cbfa-1 (Runx-2) and Osteocalcin Expression by Human Osteoblasts in Heparin Osteoporosis in Vitro
Alexander E. Handschin, MD
Department of Surgery, Research Division, University Hospital of Zurich, Switzerland, alexander.handschin{at}usz.ch
Marcus Egermann, MD
Department of Surgery, Research Division, University Hospital of Zurich, Switzerland
Otmar Trentz, MD
Division of Trauma Surgery, University Hospital of Zurich, Switzerland
Guido A. Wanner, MD
Division of Trauma Surgery, University Hospital of Zurich, Switzerland
Hans-Jürgen Kock, MD
Division of Trauma Surgery, Hochtaunus Kliniken, Bad Homburg, Germany
Gregor Zünd, MD
Department of Surgery, Research Division, University Hospital of Zurich, Switzerland
Omana Anna Trentz, MD
Department of Surgery, Research Division, University Hospital of Zurich, Switzerland
Heparin may cause adverse effects on bone formation following long-term application. The exact pathomechanism is unclear, but in vitro data suggest an impaired osteoblast function. The transcription axis of Cbfa-1 (Runx-2) and osteocalcin is crucial in maintaining an equilibrium of bone formation and resorption in vivo. We used a human osteoblast cell culture model to further investigate the effect of heparin (low-molecular-weight heparin, dalteparin) on the expression of these two regulators of osteoblast differentiation. At high doses, dalteparin caused a significant inhibition of both osteocalcin and Cbfa-1 expression in vitro. Our data support the hypothesis of a direct inhibition of osteoblast function underlying heparin osteoporosis.
Key Words: Heparin osteoporosis Osteoblast Osteocalcin Cbfa-1
References
- Griffith GC, Nichols G, Asher J, et al. Heparin osteoporosis. JAMA 1965; 193: 91-91.[CrossRef][Medline]
[Order article via Infotrieve]
- Squires JW, Pinch LW. Heparin-induced spinal fractures. JAMA 1979; 241: 2417-2417.[Abstract]
- Wise PH, Hall AJ. Heparin-induced osteopenia in pregnancy. BMJ 1980; 281: 110-110.[ISI][Medline]
[Order article via Infotrieve]
- Megard M, Cuche M, Grapeloux A. Heparin osteoporosis: Histomorphometric analyis of bone biopsy. Nouv Presse Med. 1982; 11: 261-261.[ISI][Medline]
[Order article via Infotrieve]
- Dahlmann TC. Osteoporotic fractures and the recurrence of thromboembolism during pregnancy and the puerperium in 184 women undergoing thromboprophylaxis with heparin. Am J Obstet Gynecol 1993; 168: 1265-1265.[ISI][Medline]
[Order article via Infotrieve]
- Sivakumaran M, Ghosh K, Zaidi Y, et al. Osteoporosis and vertebral collapse following low-dose, low-molecular-weight heparin therapy in a young patient. Clin Lab Haematol 1996; 18: 55-55.[ISI][Medline]
[Order article via Infotrieve]
- Douketis JD, Ginsberg JS, Burrows RF, et al. The effect of long-term heparin therapy during pregnancy on bone density. A prospective matched cohort study. Thromb Haemost 1996; 75: 254-254.[ISI][Medline]
[Order article via Infotrieve]
- Hunt BJ, Doughty HA, Majumdar G, et al. Thromboprophylaxis with low-molecular-weight heparin (Fragmin) in high-risk pregnancies. Thromb Haemost 1997; 77: 39-39.[ISI][Medline]
[Order article via Infotrieve]
- Wawrzynska L, Tomkowski WZ, Przedlacki J, et al. Changes in bone density during long-term administration of low-molecular-weight heparins or acenocoumarol for secondary prophylaxis of venous thromboembolism. Pathophysiol Haemost Thromb 2003; 33: 64-64.[Medline]
[Order article via Infotrieve]
- Kock HJ, Handschin AE. Osteoblast growth inhibition by unfractionated and by low-molecular-weight heparins: An in-vitro investigation. Clin Appl Thromb Hemost 2002; 8: 251-251.[Abstract/Free Full Text]
- Walton KJ, Duncan JM, Deschamps P, et al. Heparin acts synergistically with interleukin-11 to induce STAT3 activation and in vitro osteoclast formation. Blood 2002; 100: 2530-2530.[Abstract/Free Full Text]
- Bhandari M, Hirsh J, Weitz JI, et al. The effects of standard and low-molecular-weight heparin on bone nodule formation in vitro. Thromb Hemost 1998; 80: 413-413.[ISI][Medline]
[Order article via Infotrieve]
- Handschin AE, Trentz OA, Hoerstrup SP, et al. Effect of low-molecular-weight heparin (dalteparin) and fondaparinux (Arixtra®) on human osteoblasts in vitro. Br J Surg 2005; 92: 177-177.[CrossRef][ISI][Medline]
[Order article via Infotrieve]
- Ducy P, Desbois C, Boyce B, et al. Increased bone formation in osteocalcin-deficient mice. Nature 1996; 382: 448-448.[CrossRef][Medline]
[Order article via Infotrieve]
- Lian JB, Javed A, Zaidi SK, et al. Regulatory controls for osteoblast growth and differentiation: Role of Runx/Cbfa/AML factors. Crit Rev Eukaryot Gene Expr 2004; 14: 1-1.[ISI][Medline]
[Order article via Infotrieve]
- Lian JB, Stein GS. Runx2/Cbfa1: A multifunctional regulator of bone formation. Curr Pharm Des 2003; 9: 2677-2677.[CrossRef][Medline]
[Order article via Infotrieve]
- Ducy P. Cbfa-1: A molecular switch in osteoblast biology. Dev Dyn 2000; 219: 461-461.[CrossRef][ISI][Medline]
[Order article via Infotrieve]
- Ducy P, Zhang R, Geoffroy V, et al. Osf2/Cbfa-1: A transcriptional activator of osteoblast differentiation. Cell 1997; 89: 747-747.[CrossRef][ISI][Medline]
[Order article via Infotrieve]
- Trentz OA, Hoerstrup SP, Sun LK, et al. Osteoblasts response to allogenic and xenogenic solvent dehydrated cancellous bone in vitro. Biomaterials 2003; 24: 3417-3417.[CrossRef][ISI][Medline]
[Order article via Infotrieve]
- Mocellin S, Rossi CR, Pilati P, et al. Quantitative real-time PCR: A powerful ally in cancer research. Trends Mol Med 2003; 9: 189-189.[CrossRef][ISI][Medline]
[Order article via Infotrieve]
- Prophet EB, Mills B, Arrington JB, Sobin LH, eds. Laboratory Methods in Histotechnology of the Armed Forces Institute of Pathology, 4th ed., Washington DC: American Registry of Pathology, 1992.
- Aronow MA, Gerstenfeld LC, Owen TA, et al. Factors that promote progressive development of the osteoblast phenotype in cultured fetal rat calvaria cells. J Cell Physiol 1990; 143: 213-213.[CrossRef][ISI][Medline]
[Order article via Infotrieve]
- Trentz OA, Handschin AE, Bestman L, et al. Influence of brain injury on early posttraumatic bone metabolism. Crit Care Med 2005; 33: 399-399.[CrossRef][ISI][Medline]
[Order article via Infotrieve]
- Banerjee C, et al. Differential regulation of two principal Runx2/Cbfa-1 n-terminal isoforms in response to bone morphogenetic protein-2 during development of the osteoblast phenotype. Endocrinology 2001; 142: 4026-4026.[Abstract/Free Full Text]
- Komori T, Yagi H, Nomura S, et al. Targeted disruption of Cbfa-1 results in a complete lack of bone formation owing to maturational arrest of osteoblasts. Cell 1997; 89: 755-755.[CrossRef][ISI][Medline]
[Order article via Infotrieve]
- Otto F, Thornell AP, Crompton T, et al. Cbfa-1, a candidate gene for cleidocranial dysplasia syndrome, is essential for osteoblast differentiation and bone development. Cell 1997; 89: 765-765.[CrossRef][ISI][Medline]
[Order article via Infotrieve]
- Liu W, Toyosawa S, Furuichi T, et al. Overexpression of Cbfa-1 in osteoblasts inhibits osteoblast maturation and causes osteopenia with multiple fractures. J Cell Biol 2001; 155: 157-157.[Abstract/Free Full Text]
- Phan TC, Xu J, Zheng MH. Interaction between osteoblast and osteoclast: Impact in bone disease. Histol Histopathol 2004; 19: 1325-1325.[ISI][Medline]
[Order article via Infotrieve]
- Fuller K, Chambers TJ, Gallagher AC. Heparin augments osteoclast resorption-stimulating activity in serum. J Cell Physiol 1991; 147: 208-208.[CrossRef][ISI][Medline]
[Order article via Infotrieve]
- Hauser HJ, Brenner RE. Low doses and high doses of heparin have different effects on osteoblast-like Saos-2 cells in vitro. J Cell Biochem 2004; 91: 1062-1062.[CrossRef][ISI][Medline]
[Order article via Infotrieve]
- Pautke C, Schieker M, Tischer T. Characterization of osteosarcoma cell lines MG-63, Saos-2 and U-2 OS in comparison to human osteoblasts. Anticancer Res 2004; 24: 3743-3743.[ISI][Medline]
[Order article via Infotrieve]
- Dahl OE, Pleil AM. Investment in prolonged thromboprophylaxis with dalteparin improves clinical outcomes after hip replacement. J Thromb Haemost 2003; 1: 896-896.[CrossRef][ISI][Medline]
[Order article via Infotrieve]
- Kolb G, Bodamer I, Galster H, et al. Reduction of venous thromboembolism following prolonged prophylaxis with the low-molecular-weight heparin Certoparin after endo-prosthetic joint replacement or osteosynthesis of the lower limb in elderly patients. Thromb Haemost 2003; 90: 1100-1100.[ISI][Medline]
[Order article via Infotrieve]

CiteULike Connotea Del.icio.us Digg Reddit Technorati What's this?
|